Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials

Published:2023-11 Issue:11 Volume:34 Page:1003-1014
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

André F.,Su F.,Solovieff N.,Hortobagyi G.,Chia S.,Neven P.,Bardia A.,Tripathy D.,Lu Y.-S.,Lteif A.,Taran T.,Babbar N.,Slamon D.,Arteaga C.L.

Funder

Novartis Pharmaceuticals Corporation

Novartis

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference52 articles.

1. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers;Finn;Breast Cancer Res,2016

2. Comprehensive molecular portraits of human breast tumours;Nature,2012

3. Cell-cycle therapeutics come of age;Ingham;J Clin Oncol,2017

4. The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer;Peurala;Breast Cancer Res,2013

5. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer;Bosco;J Clin Invest,2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy;Cancers;2024-04-30

2. Circulating tumor DNA validity and potential uses in metastatic breast cancer;npj Breast Cancer;2024-03-12

3. Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer;2024-02-08

4. Cracking the Genomic Code of CDK4/6 Inhibitor Resistance;Clinical Cancer Research;2024-02-06

5. The CDK4/6 inhibitors biomarker landscape: The most relevant biomarkers of response or resistance for further research and potential clinical utility;Critical Reviews in Oncology/Hematology;2023-12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3